{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:14:43Z","timestamp":1787062483157,"version":"build-2736575974"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Some schizophrenia patients treated with clozapine experience an inadequate response and adherence problems. The purpose of this study was to compare time to rehospitalization within 6 months in schizophrenia patients discharged on 3 clozapine regimens. Additionally, the temporal trend of prescription rate in each group was also explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Schizophrenia patients discharged from the study hospital from January 1, 2006, to December 31, 2021, (n\u2009=\u20093271) were included in the analysis. The type of clozapine prescribed at discharge was divided into 3 groups: clozapine plus long-acting injectable antipsychotics (clozapine + LAIs), clozapine plus other oral antipsychotics (clozapine + OAPs), and clozapine monotherapy. Survival analysis was used to compare time to rehospitalization within 6 months after discharge among the 3 groups. The temporal trend in the prescription rate of each group was analyzed using the Cochran-Armitage Trend test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients discharged on clozapine + LAIs had a significantly longer time to rehospitalization than those on clozapine + OAPs or clozapine monotherapy. The prescription rates of clozapine + LAIs and clozapine + OAPs significantly increased over time, whereas the prescription rates of clozapine monotherapy significantly decreased.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with the clozapine + OAPs group, the clozapine + LAIs group had a lower risk of rehospitalization and a lower dose of clozapine prescribed. Therefore, if a second antipsychotic is required for patients who are taking clozapine alone, LAIs should be considered earlier.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyad053","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T11:46:00Z","timestamp":1692704760000},"page":"808-816","source":"Crossref","is-referenced-by-count":9,"title":["Schizophrenia Patients Discharged on Clozapine Plus Long-Acting Injectable Antipsychotics From a Public Psychiatric Hospital in Taiwan, 2006\u20132021"],"prefix":"10.1093","volume":"26","author":[{"given":"Ta-Chun","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hua","family":"Lin","sequence":"additional","affiliation":[{"name":"Kaohsiung Municipal Kai-Syuan Psychiatric Hospital , Kaohsiung , Taiwan"},{"name":"Department of Psychiatry, School of Medicine, College of Medicine, Kaohsiung Medical University , Kaohsiung , Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Sun Yat-sen University , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"2023112505433854100_CIT0001","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4088\/JCP.v59n0906","article-title":"Clozapine withdrawal-emergent dystonias and dyskinesias: a case series","volume":"59","author":"Ahmed","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"2023112505433854100_CIT0002","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-5","author":"APA (American Psychiatric Association)","year":"2013"},{"key":"2023112505433854100_CIT0003","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-IV-TR","author":"APA","year":"2000","edition":"4"},{"key":"2023112505433854100_CIT0004","volume-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","author":"APA","year":"2021","edition":"3"},{"key":"2023112505433854100_CIT0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-244X-10-2","article-title":"The cost of relapse and the predictors of relapse in the treatment of schizophrenia","volume":"10","author":"Ascher-Svanum","year":"2010","journal-title":"BMC Psychiatry"},{"key":"2023112505433854100_CIT0006","first-page":"CD006324","article-title":"Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia","volume":"3","author":"Barber","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2023112505433854100_CIT0007","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1192\/j.eurpsy.2020.72","article-title":"Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: a retrospective 6-month mirror-image study","volume":"63","author":"Bioque","year":"2020","journal-title":"Eur Psychiatry"},{"key":"2023112505433854100_CIT0008","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/YIC.0000000000000336","article-title":"The effects of adding long-acting injectable antipsychotic drugs to clozapine on relapse and hospitalization in patients with treatment-resistant schizophrenia: a mirror-image retrospective study","volume":"36","author":"Caliskan","year":"2021","journal-title":"Int Clin Psychopharmacol"},{"key":"2023112505433854100_CIT0009","doi-asserted-by":"crossref","first-page":"429","DOI":"10.5498\/wjp.v11.i8.429","article-title":"Clozapine resistant schizophrenia: newer avenues of management","volume":"11","author":"Chakrabarti","year":"2021","journal-title":"World J Psychiatry"},{"key":"2023112505433854100_CIT0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence","volume":"77","author":"Correll","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"2023112505433854100_CIT0011","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/acps.12233","article-title":"Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients","volume":"130","author":"Davis","year":"2014","journal-title":"Acta Psychiatr Scand"},{"key":"2023112505433854100_CIT0012","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.psc.2016.01.006","article-title":"Treatment-resistant schizophrenia","volume":"39","author":"Elkis","year":"2016","journal-title":"Psychiatr Clin North Am"},{"key":"2023112505433854100_CIT0013","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0893-133X(02)00319-6","article-title":"Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia","volume":"27","author":"Fabrazzo","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"2023112505433854100_CIT0014","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4088\/JCP.18ac12394","article-title":"Treatment-resistant schizophrenia: a brief overview of treatment options","volume":"80","author":"Faden","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"2023112505433854100_CIT0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.psychres.2016.11.044","article-title":"Clinical trial methodology to assess the efficacy\/effectiveness of long-acting antipsychotics: randomized controlled trials vs naturalistic studies","volume":"247","author":"Fagiolini","year":"2017","journal-title":"Psychiatry Res"},{"key":"2023112505433854100_CIT0016","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/bjb.2018.67","article-title":"Barriers to using clozapine in treatment-resistant schizophrenia: systematic review","volume":"43","author":"Farooq","year":"2019","journal-title":"BJPsych Bull"},{"key":"2023112505433854100_CIT0017","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1192\/bjp.bp.110.088690","article-title":"Clozapine: dangerous orphan or neglected friend","volume":"198","author":"Farooq","year":"2011","journal-title":"Br J Psychiatry"},{"key":"2023112505433854100_CIT0018","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1080\/00048670701579025","article-title":"Australian Schizophrenia Care and Assessment Programme: real-world schizophrenia: economics","volume":"41","author":"Fitzgerald","year":"2007","journal-title":"Aust N Z J Psychiatry"},{"key":"2023112505433854100_CIT0019","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1017\/S1461145712000399","article-title":"Critical review of antipsychotic polypharmacy in the treatment of schizophrenia","volume":"17","author":"Fleischhacker","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"2023112505433854100_CIT0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-199732020-00001","article-title":"Will routine therapeutic drug monitoring have a place in clozapine therapy","volume":"32","author":"Freeman","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"2023112505433854100_CIT0021","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jad.2011.10.033","article-title":"Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009","volume":"136","author":"Greil","year":"2012","journal-title":"J Affect Disord"},{"key":"2023112505433854100_CIT0022","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4088\/PCC.19m02560","article-title":"Combination of clozapine with long-acting injectable antipsychotics in treatment-resistant schizophrenia: preliminary evidence from health care utilization indices","volume":"22","author":"Grimminck","year":"2020","journal-title":"Prim Care Companion CNS Disord"},{"key":"2023112505433854100_CIT0023","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/acps.13406","article-title":"Recognition and management of clozapine adverse effects: a systematic review and qualitative synthesis","volume":"145","author":"Gurrera","year":"2022","journal-title":"Acta Psychiatr Scand"},{"key":"2023112505433854100_CIT0024","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/archpsyc.63.7.817","article-title":"Acetaldehyde involvement in positive and negative alcohol expectancies in Han Chinese persons with alcoholism","volume":"63","author":"Hahn","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"2023112505433854100_CIT0025","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am J Psychiatry"},{"key":"2023112505433854100_CIT0026","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.euroneuro.2022.03.010","article-title":"Comparative effectiveness of antipsychotic monotherapy and polypharmacy in schizophrenia patients with clozapine treatment: a nationwide, health insurance data-based study","volume":"59","author":"Joo","year":"2022","journal-title":"Eur Neuropsychopharmacol"},{"key":"2023112505433854100_CIT0027","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"2023112505433854100_CIT0028","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0269881109348174","article-title":"The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series","volume":"24","author":"Kim","year":"2010","journal-title":"J Psychopharmacol"},{"key":"2023112505433854100_CIT0029","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"2023112505433854100_CIT0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.schres.2016.05.002","article-title":"Reasons for discontinuing clozapine: a cohort study of patients commencing treatment","volume":"174","author":"Legge","year":"2016","journal-title":"Schizophr Res"},{"key":"2023112505433854100_CIT0059","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am J Psychiatry"},{"key":"2023112505433854100_CIT0031","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD method","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophr Bull"},{"key":"2023112505433854100_CIT0032","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1176\/appi.ajp.2021.21080825","article-title":"Clozapine, long-acting injectables (and Polypharmacy?) superior in U.S. and international registries","volume":"178","author":"Leucht","year":"2021","journal-title":"Am J Psychiatry"},{"key":"2023112505433854100_CIT0033","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-0034-1390469","article-title":"Antipsychotic agents used to augment clozapine during long-term inpatient hospitalizations","volume":"47","author":"Leung","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"2023112505433854100_CIT0034","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00127-018-1606-y","article-title":"Compulsory admission is associated with an increased risk of readmission in patients with schizophrenia: a 7-year, population-based, retrospective cohort study","volume":"54","author":"Lin","year":"2019","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"2023112505433854100_CIT0035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/ijnp\/pyz035","article-title":"Time to rehospitalization in patients with schizophrenia receiving long-acting injectable antipsychotics or oral antipsychotics","volume":"22","author":"Lin","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"2023112505433854100_CIT0036","doi-asserted-by":"crossref","first-page":"e12525","DOI":"10.1111\/appy.12525","article-title":"Fourteen-year trends in the prescribing patterns of pediatric bipolar patients discharged from two public mental hospitals in Taiwan","volume":"15","author":"Lin","year":"2023","journal-title":"Asia Pac Psychiatry"},{"key":"2023112505433854100_CIT0037","doi-asserted-by":"crossref","first-page":"30S","DOI":"10.1177\/088740341305805s05","article-title":"Long-acting injectable antipsychotics: recommendations for clinicians","volume":"58","author":"Malla","year":"2013","journal-title":"Can J Psychiatry"},{"key":"2023112505433854100_CIT0038","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/schbul\/18.3.515","article-title":"Treatment of the neuroleptic-nonresponsive schizophrenic patient","volume":"18","author":"Meltzer","year":"1992","journal-title":"Schizophr Bull"},{"key":"2023112505433854100_CIT0039","first-page":"775","article-title":"Therapeutics of schizophrenia","volume-title":"Neuropsychopharmacology: the fifth generation of progress","author":"Miyamoto","year":"2002"},{"key":"2023112505433854100_CIT0040","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/archpsyc.64.9.1032","article-title":"National trends in the outpatient diagnosis and treatment of bipolar disorder in youth","volume":"64","author":"Moreno","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"2023112505433854100_CIT0041","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-244X-8-32","article-title":"Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia","volume":"8","author":"Morken","year":"2008","journal-title":"BMC Psychiatry"},{"key":"2023112505433854100_CIT0042","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1517\/14656566.2014.956082","article-title":"Augmentation strategies in partial responder and\/or treatment-resistant schizophrenia patients treated with clozapine","volume":"15","author":"Muscatello","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"2023112505433854100_CIT0043","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/JCP.0000000000001526","article-title":"Combination With long-acting injectable antipsychotics and utilization of nonstandard formulations as compliance enhancing methods for clozapine users: a systematic review and a case series","volume":"42","author":"Mutlu","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"2023112505433854100_CIT0044","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0447.2011.01710.x","article-title":"Optimizing clozapine treatment","volume":"123","author":"Nielsen","year":"2011","journal-title":"Acta Psychiatr Scand"},{"key":"2023112505433854100_CIT0045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1744-859X-12-32","article-title":"Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review","volume":"12","author":"Olivares","year":"2013","journal-title":"Ann Gen Psychiatry"},{"key":"2023112505433854100_CIT0046","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1176\/appi.ps.57.1.21","article-title":"Best practices: an initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital","volume":"57","author":"Patrick","year":"2006","journal-title":"Psychiatr Serv"},{"key":"2023112505433854100_CIT0047","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/14740338.2016.1191468","article-title":"Clozapine\u2019s critical role in treatment resistant schizophrenia: ensuring both safety and use","volume":"15","author":"Remington","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2023112505433854100_CIT0048","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1176\/appi.ajp.2020.19091000","article-title":"20-year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings","volume":"177","author":"Rhee","year":"2020","journal-title":"Am J Psychiatry"},{"key":"2023112505433854100_CIT0049","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0004867413488221","article-title":"Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison","volume":"48","author":"Roh","year":"2014","journal-title":"Aust N Z J Psychiatry"},{"key":"2023112505433854100_CIT0050","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/schbul\/22.4.591","article-title":"Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal","volume":"22","author":"Shiovitz","year":"1996","journal-title":"Schizophr Bull"},{"key":"2023112505433854100_CIT0051","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.schres.2017.01.036","article-title":"Clozapine and long-acting injectable antipsychotic combination: a retrospective one-year mirror-image study","volume":"188","author":"Souaiby","year":"2017","journal-title":"Schizophr Res"},{"key":"2023112505433854100_CIT0052","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/jamaneurol.2013.95","article-title":"Serotonin syndrome associated with clozapine withdrawal","volume":"70","author":"Stevenson","year":"2013","journal-title":"JAMA Neurol"},{"key":"2023112505433854100_CIT0053","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hup.842","article-title":"Metabolic differences between Asian and Caucasian patients on clozapine treatment","volume":"22","author":"Subramaniam","year":"2007","journal-title":"Hum Psychopharmacol"},{"key":"2023112505433854100_CIT0054","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1192\/bjp.bp.108.051979","article-title":"Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection","volume":"194","author":"Taylor","year":"2009","journal-title":"Br J Psychiatry"},{"key":"2023112505433854100_CIT0055","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","article-title":"Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia","volume":"76","author":"Tiihonen","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"2023112505433854100_CIT0056","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.12669\/pjms.37.5.3961","article-title":"Clinical outcome of right ventricle outflow tract management for repair of Tetralogy of Fallot with three contemporary surgical strategies","volume":"37","author":"Waqar","year":"2021","journal-title":"Pak J Med Sci"},{"key":"2023112505433854100_CIT0060","article-title":"ATC\/DDD Index N04A Anticholinergic agents","author":"World Health Organization","year":"2023"},{"key":"2023112505433854100_CIT0058","first-page":"543","article-title":"The Chinese drinking problem: a review of the literature and its implication in a cross-cultural study","volume":"18","author":"Yang","year":"2002","journal-title":"Kaohsiung J Med Sci"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyad053\/51544260\/pyad053.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/26\/11\/808\/53799849\/pyad053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/26\/11\/808\/53799849\/pyad053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:44:17Z","timestamp":1700873057000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/26\/11\/808\/7250149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":59,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,8,24]]},"published-print":{"date-parts":[[2023,11,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyad053","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,8,24]]}}}